Ongoing Clinical Trials Related to Haemofiltration
There is currently 1 ongoing clinical trial investigating haemofiltration treatment. This trial focuses on optimizing antibiotic dosing for critically ill patients undergoing continuous renal replacement therapy, a form of dialysis used when the kidneys are severely compromised.
Clinical trial locations
- Belgium
- Spain
- Sweden
Study on Optimizing Ceftazidime-Avibactam Dosing for Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
This clinical trial is designed for critically ill patients who are undergoing continuous renal replacement therapy, a specialized form of dialysis used when the kidneys are severely impaired. The study investigates how to best dose a combination antibiotic medication called ceftazidime-avibactam in this specific patient population.
Main inclusion criteria:
- The participant or their legal representative must provide written informed consent before any study procedures begin
- Must be 18 years of age or older
- Must be admitted to an intensive care unit
- Must be receiving treatment with ceftazidime-avibactam
- Must be undergoing any form of continuous renal replacement therapy
- Must use highly effective birth control methods with less than 1% failure rate per year when used correctly, such as implants, injectables, combined oral contraceptives, certain IUDs, complete sexual abstinence, or having a partner who has had a vasectomy
Main exclusion criteria:
- Patients who are not critically ill
- Patients who are not undergoing continuous renal replacement therapy
- Patients who do not meet the specified age range for the study
- Patients who do not meet other specific health conditions required for the study
Focus and goal of the trial:
The primary purpose of this study is to develop an optimized dosing regimen for ceftazidime-avibactam in critically ill patients receiving continuous renal replacement therapy. Researchers will closely monitor how the body absorbs and processes the medication, a process known as pharmacokinetics. The goal is to ensure that the medication reaches the right levels in the body to effectively fight serious bacterial infections while minimizing potential side effects. The trial will collect data until June 2026 to create a model that helps determine the best dosing strategy for this patient population.
Investigational drug:
The medication being studied is ceftazidime-avibactam, a combination antibiotic administered directly into a vein. Ceftazidime is an antibiotic that stops bacteria from building their protective cell walls, while avibactam protects ceftazidime from being broken down by certain bacterial enzymes. This combination is particularly useful for treating serious bacterial infections caused by resistant strains, especially in critically ill patients whose kidneys are not functioning properly.
Summary
Currently, there is one clinical trial investigating haemofiltration, specifically focusing on optimizing antibiotic treatment for patients undergoing continuous renal replacement therapy. This trial is being conducted across three European countries: Belgium, Spain, and Sweden. The study addresses an important clinical challenge: determining the appropriate antibiotic dosing for critically ill patients whose kidney function is severely compromised and who require specialized dialysis treatment.
The focus on ceftazidime-avibactam reflects the growing concern about treating serious bacterial infections in vulnerable patient populations, particularly those with resistant bacterial strains. The trial’s emphasis on pharmacokinetic monitoring demonstrates a personalized medicine approach, aiming to ensure that each patient receives the most effective dose of medication based on how their body processes it during continuous renal replacement therapy.